Biotechnology The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) – a type of tumor that forms on nerves, who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. 12 February 2025